BILI vs META

The Advanced Deterministic Scorecard reveals significant concerns with a weak Piotroski F-Score of 2/9, indicating poor financial health, and the absence of an Altman Z-Score limits distress risk assessment. Despite this, BILI shows strong recent price momentum with a 1Y return of +103.3%, robust revenue surprise trends, and a bullish analyst recommendation, offset by stretched valuation metrics such as a P/E of 128.46 versus a sector average of 19.92. Profitability margins and ROE remain below peer averages, while improving earnings surprises and cash flow trends suggest potential operational turnaround. The stock trades at a large premium to both Graham Number ($5.47) and intrinsic value ($1.82), implying high growth expectations are already priced in.

META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across profitability, leverage, and operating efficiency. While the current price of $612.42 trades at a premium to the Graham Number ($213.17) and the growth-based Intrinsic Value ($542.14), the PEG ratio of 0.94 suggests the stock is undervalued relative to its high growth rate. Strong revenue growth (23.8%) and a low forward P/E (17.03) outweigh the bearish technical trend and insider selling. The company's dominant market position and consistent earnings beats support a bullish long-term outlook.